Limonexic acidCAS# 99026-99-0 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 99026-99-0 | SDF | Download SDF |
| PubChem ID | 5321283 | Appearance | Powder |
| Formula | C26H30O10 | M.Wt | 502.5 |
| Type of Compound | Triterpenoids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| SMILES | CC1(C2CC(=O)C3(C(C24COC(=O)CC4O1)CCC5(C36C(O6)C(=O)OC5C7=CC(=O)OC7O)C)C)C | ||
| Standard InChIKey | RTPPVNISJHFPFX-PEVOZZQFSA-N | ||
| Standard InChI | InChI=1S/C26H30O10/c1-22(2)13-8-14(27)24(4)12(25(13)10-32-16(28)9-15(25)35-22)5-6-23(3)18(11-7-17(29)33-20(11)30)34-21(31)19-26(23,24)36-19/h7,12-13,15,18-20,30H,5-6,8-10H2,1-4H3/t12-,13-,15-,18-,19+,20?,23-,24-,25+,26+/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Limonexic acid shows antinociceptive actions , it produces dose-related inhibition of glutamate- and capsaicin-induced pain. 2. Limonexic acid can effectively protect hepatocyte against CCl4-induced injury. |
| Targets | GABA Receptor |
Limonexic acid Dilution Calculator
Limonexic acid Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.99 mL | 9.9502 mL | 19.9005 mL | 39.801 mL | 49.7512 mL |
| 5 mM | 0.398 mL | 1.99 mL | 3.9801 mL | 7.9602 mL | 9.9502 mL |
| 10 mM | 0.199 mL | 0.995 mL | 1.99 mL | 3.9801 mL | 4.9751 mL |
| 50 mM | 0.0398 mL | 0.199 mL | 0.398 mL | 0.796 mL | 0.995 mL |
| 100 mM | 0.0199 mL | 0.0995 mL | 0.199 mL | 0.398 mL | 0.4975 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- [Ala113]-MBP (104-118)
Catalog No.:BCC5836
CAS No.:99026-78-5
- [Ala107]-MBP (104-118)
Catalog No.:BCC5835
CAS No.:99026-77-4
- Imiquimod hydrochloride
Catalog No.:BCC4196
CAS No.:99011-78-6
- Imiquimod
Catalog No.:BCC2492
CAS No.:99011-02-6
- Fentanyl citrate
Catalog No.:BCC6000
CAS No.:990-73-8
- 4-Hydroxybenzoic acid
Catalog No.:BCN4546
CAS No.:99-96-7
- 4'-Hydroxyacetophenone
Catalog No.:BCN4544
CAS No.:99-93-4
- 4-Isopropyltoluene
Catalog No.:BCC8282
CAS No.:99-87-6
- Methyl 4-hydroxybenzoate
Catalog No.:BCN4540
CAS No.:99-76-3
- Valproic acid
Catalog No.:BCC4260
CAS No.:99-66-1
- 3,4-Dihydroxybenzoic acid
Catalog No.:BCN4537
CAS No.:99-50-3
- 2-Methyl-5-Isopropenyl-2-Cyclohexenone
Catalog No.:BCC8279
CAS No.:99-49-0
- Kushenol I
Catalog No.:BCN2983
CAS No.:99119-69-4
- Kushenol E
Catalog No.:BCN3348
CAS No.:99119-72-9
- Kushenol C
Catalog No.:BCN3351
CAS No.:99119-73-0
- Yadanzioside I
Catalog No.:BCN6715
CAS No.:99132-95-3
- Yadanzioside L
Catalog No.:BCN6713
CAS No.:99132-97-5
- Dehydrobruceantinol
Catalog No.:BCN7621
CAS No.:99132-99-7
- 1,6,8-Trideoxyshanzhigenin
Catalog No.:BCN6909
CAS No.:99173-00-9
- Salannin
Catalog No.:BCN8052
CAS No.:992-20-1
- Anpirtoline hydrochloride
Catalog No.:BCC6754
CAS No.:99201-87-3
- Kushenol A
Catalog No.:BCN2982
CAS No.:99217-63-7
- Kushenol B
Catalog No.:BCN3313
CAS No.:99217-64-8
- Caesalpin J
Catalog No.:BCC8305
CAS No.:99217-67-1
Limonoids and their anti-proliferative and anti-aromatase properties in human breast cancer cells.[Pubmed:23117440]
Food Funct. 2013 Feb;4(2):258-65.
Lemons are a widely used citrus crop and have shown several potential health benefits. In the present study, the mechanism and effectiveness of the anti-cancer and anti-aromatase properties of limonoids were investigated for the first time. Defatted lemon (Citrus lemon L. Burm) seed powder was extracted with ethyl acetate (EtOAc) and methanol (MeOH) for 16 h each, successively. These extracts were fractionated using 1D (silica) and 2D (ion exchange and SP-70 columns) column chromatography to obtain nine limonoids. The compounds were identified by TLC, HPLC, and LC-MS techniques. A panel of 9 purified limonoids, including limonin, nomilin, obacunone, Limonexic acid (LNA), isoLimonexic acid (ILNA), nomilinic acid glucoside (NAG), deacetyl nomilinic acid glucoside (DNAG), limonin glucoside (LG) and obacunone glucoside (OG) as well as 4 modified compounds such as limonin methoxime (LM), limonin oxime (LO), defuran limonin (DL), and defuran nomilin (DN), were screened for their cytotoxicity on estrogen receptor (ER)-positive (MCF-7) or ER-negative (MDA-MB-231) human breast cancer cells. We further tested the mechanism of the anti-proliferative activity of limonoids using an in vitro aromatase enzyme assay and western blot with anti-caspase-7. Among the tested limonoids, 11 limonoids exhibited cytotoxicity on MCF-7 whereas 8 limonoids showed cytotoxicity against the MDA-MB-231 cell lines. Although most of the limonoids showed anti-aromatase activity, the inhibition of proliferation was not related to the anti-aromatase activity. On the other hand, the anti-proliferative activity was significantly correlated with caspase-7 activation by limonoids. Our findings indicated that the citrus limonoids may have potential for the prevention of estrogen-responsive breast cancer (MCF-7) via caspase-7 dependent pathways.
Protective effect of compounds from the flowers of Citrus aurantium L. var. amara Engl against carbon tetrachloride-induced hepatocyte injury.[Pubmed:23985451]
Food Chem Toxicol. 2013 Dec;62:432-5.
5-Hydroxy-6,7,3',4'-tetramethoxyflavone (HTF), Limonexic acid (LA) are two compounds isolated from the flowers of Citrus aurantium L. var. amara Engl with various biological activities. This study was designed to investigate their protective effects against carbon tetrachloride (CCl4)-induced hepatocyte injury, using human hepatic cell line HL-7702 to determine the cell cytotoxicity, cell viability, levels of hepatic marker enzymes, malondialdehyde (MDA). Results showed that pretreatment with HTF, LA could significantly reverse CCl4-induced HL-7702 cell viability decrease, LA displayed a higher activity. HTF, LA also showed their capability of decreasing the CCl4-induced leakage of lactate dehydrogenase (LDH), aspartate aminotransferase (AST), inhibiting the lipid peroxidation, HTF showed more significant activity. Given that HTF, LA were not toxic, it is concluded that HTF, LA could effectively protect hepatocyte against CCl4-induced injury.
Antinociceptive action of limonexic acid obtained from Raulinoa echinata.[Pubmed:17976270]
J Pharm Pharmacol. 2007 Nov;59(11):1573-81.
The antinociceptive effect of the Limonexic acid isolate of Raulinoa echinata Cowan in four models of pain in mice is described. When evaluated against acetic acid-induced abdominal constrictions, Limonexic acid (10, 30 and 60 mg kg(-1), i.p.) produced dose-related inhibition of the number of constrictions, with a mean ID50 value of 43 (2.3-79) micromol kg(-1), and was more potent than some standard drugs. In the formalin test, Limonexic acid inhibited both the first and second phases of formalin-induced pain. Furthermore, the effect was more pronounced in the second phase, with a mean ID50 value of 13.66 (9.35-19.61) micromol kg(-1), and had a pharmacological profile that was similar to standard drugs such as acetaminophen and acetyl salicylic acid. Limonexic acid also produced dose-related inhibition of glutamate- and capsaicin-induced pain, with mean ID50 values of 11.67 (8.51-16.0) micromol kg(-1) and 47.17 (36.51-60.93) micromol kg(-1), respectively. The mechanism of action is not completely understood, but seems to involve direct interaction with the GABAergic and nitroxidergic pathways.
